glycyl-arginyl-glycyl-aspartyl-seryl-proline has been researched along with thapsigargin in 1 studies
| Studies (glycyl-arginyl-glycyl-aspartyl-seryl-proline) | Trials (glycyl-arginyl-glycyl-aspartyl-seryl-proline) | Recent Studies (post-2010) (glycyl-arginyl-glycyl-aspartyl-seryl-proline) | Studies (thapsigargin) | Trials (thapsigargin) | Recent Studies (post-2010) (thapsigargin) |
|---|---|---|---|---|---|
| 162 | 1 | 20 | 5,234 | 3 | 918 |
| Protein | Taxonomy | glycyl-arginyl-glycyl-aspartyl-seryl-proline (IC50) | thapsigargin (IC50) |
|---|---|---|---|
| Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 | Oryctolagus cuniculus (rabbit) | 0.002 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chung, KH; Hwang, KA; Kim, TJ; Lee, YH; Ryu, CK; Song, YS; Yun, YP; Zhang, YH | 1 |
1 other study(ies) available for glycyl-arginyl-glycyl-aspartyl-seryl-proline and thapsigargin
| Article | Year |
|---|---|
Antiplatelet mechanism of 2-chloro-3-(4-hexylphenyl)-amino-1,4-naphthoquinone (NQ304), an antithrombotic agent.
Topics: Adenosine Triphosphate; Arachidonic Acid; Calcium; Dose-Response Relationship, Drug; Fibrinogen; Fluorescein-5-isothiocyanate; Humans; Naphthoquinones; Oligopeptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Signal Transduction; Thapsigargin; Thrombin; Thromboxane A2 | 2001 |